will maximize the combined established
portfolio. The addition of Allergan’s
Women’s Health and Anti-Infectives
portfolio will add depth to Pfizer’s
established business, and Pfizer will
expand the reach of Allergan’s
established portfolio using its existing
commercial capabilities, infrastructure
and global scale. In addition, Allergan
brings topical formulation, manufacturing and its Anda distribution
capabilities to the combined
company.
Under the terms of the proposed
transaction, the businesses of Pfizer
and Allergan will be combined under
Allergan plc, which will be renamed
“Pfizer plc.” The companies expect
that shares of the combined company
will be listed on the New York Stock
Exchange and trade under the “PFE”
ticker. Upon the closing of the transaction, the combined company is
expected to maintain Allergan’s Irish
legal domicile. Pfizer plc will have its
global operational headquarters in
New York and its principal executive
offices in Ireland.
Pfizer’s innovative businesses will be
significantly enhanced by the addition
of a growing revenue stream from
Allergan’s durable and innovative
flagship brands in desirable therapeutic
areas such as Aesthetics and Dermatology, Eye Care, Gastrointestinal,
Neuroscience and Urology. The
combined company will benefit from
a broader innovative portfolio of leading
medicines in key categories and a
platform for sustainable growth with
diversified payer groups. With the
addition of Allergan, Pfizer will enhance
its R&D capabilities in both new
molecular entities and product line
extensions. A combined pipeline of
more than 100 mid-to-late stage
programs in development and greater
resources to invest in R&D and manufacturing is expected to sustain the
growth of the innovative business
over the long term. Through product
approvals, launches and inline
performance the combined company
aspires to be a leader in growth.
The combination of Pfizer and
Allergan will significantly increase the
scale of Pfizer’s established business,
and their complementary capabilities
As a result of the combination with
Allergan and subsequent integration
of the two companies, Pfizer now
expects to make a decision about a
potential separation of the combined
company’s innovative and established
businesses by no later than the end
of 2018.